All In Biotech

NDA 021997 · Viatris

Edluar

Zolpidem Tartrate · Sublingual

Last checked: Nov 19, 2026Latest source record: Aug 18, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Mar 13, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

142

25 Phase 3, 8 recruiting

FAERS reports

24,224

18,178 serious, 3,298 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of Edluar. Some of these events may result in serious injuries, including death. Discontinue Edluar immediately if a patient experiences a complex sleep behavior [see Contraindications (4) and Warnings and Precautions (5.1) ]. WARNING: COMPLEX SLEEP BEHAVIORS See full prescribing information for complete boxed warning. Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of Edluar. Some of these events may result in serious injuries, including death. Discontinue Edluar immediately if a patient experiences a complex sleep behavior. ( 4 , 5.1 )

What it is approved for

From the label in effect Aug 15, 2022.

Edluar (zolpidem tartrate) sublingual tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation [see Clinical Studies (14) ] . The clinical trials performed with zolpidem tartrate in support of efficacy were 4-5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment. Edluar, a gamma-aminobutyric acid (GABA) A receptor positive modulator, is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem tartrate has been shown to decrease sleep latency for up to 35 days in controlled clinical studies. ( 1 )

Mechanism: Zolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia through binding to the benzodiazepine site of α 1 subunit containing GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • EDLUAR · ZOLPIDEM TARTRATE 5MG · TABLET, SUBLINGUAL · Prescription · TE AB
  • EDLUAR · ZOLPIDEM TARTRATE 10MG · TABLET, SUBLINGUAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Zolpidem" as an intervention, any sponsor and status, largest first.

All 142 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,466
  • nausea1,248
  • fatigue1,173
  • insomnia997
  • diarrhoea941
  • fall935
  • headache920
  • completed suicide894
  • pain812
  • vomiting808
  • dizziness801
  • somnolence778

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004528
2005572
2006578
2007726
2008618
2009604
2010600
2011660
2012875
2013603
2014609
20151,083
20161,591
20171,309
20181,686
20191,476
20201,330
20211,245
20221,571
20231,543
20241,688
20251,541
20261,188

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Edluar (Zolpidem Tartrate)

2024 spending

$739K

Beneficiaries

232

1,219 claims

Per beneficiary

$3,186

$14.13 per unit

View as table
YearSpending
2020$0
2021$0
2022$182,349
2023$721,541
2024$739,195

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 490 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.